Evaluation of Novel Diagnostic Tests for COVID-19

Summary

COVID-19 (also known as Coronavirus) originated in the Wuhan China and has since spread to at least 159 countries around the world. It was declared a pandemic by the World health organisation on the 11th of March 2020. The cases in the United Kingdom continue to increase exponentially with up to 5 683 people diagnosed as on the 22nd of March 2020. It is estimated that 1 in 5 people diagnosed will require hospital admission and 1 in 20 intensive care treatment. By developing and improving diagnostic testing, we can accurately diagnose infected cases to triage appropriate treatments, identify individuals for quarantine in order to prevent transmission and obtain information regarding patient's immune systems.

At present, the diagnostic test is a highly specific method of genetic amplification called 'Reverse Transcription - Polymerase Chain Reaction' or RT-PCR, which allows detection of very small amounts of genetic mutations caused by the COVID-19 virus. However, this method must be completed in highly specialised facilities, which are few and far between, increasing time to diagnosis (currently 48-72 hours), increasing exposure to non-infected individuals, and overburdening the analysing facilities. The ideal solution is a point of care (POC) test that can give results immediately. This study aims to harness the point of care technology of the SAMBA II device (Diagnostics for the Real World Ltd.), which is a CE-marked device that has been used with success in the identification of Human Immunodeficiency Virus (HIV), by amplifying genetic material without the need to increase and decrease temperatures during the amplification process.

In the COVIDx study, 200 patients meeting the Public Health England's (PHE) inpatient definition of having suspected COVID-19 will be approached, consented and a sample from throat and nasal swab (combined) or tracheal fluid taken and tested using the SAMBA II method. A combination of the standard PHE RT-PCR and an additional validated laboratory PCR technique will be used as a control in line with standard clinical practice. Patients will undergo an additional serum tests on existing samples as made available after routine clinical assessments to monitor antibody response. Patients will be followed for clinical outcomes at 28 days post-admission.

Conditions

• Acute Disease
• Coronavirus
• Respiratory Viral Infection

Interventions

DIAGNOSTIC_TEST

SAMBA II (Diagnostic for the Real World)

Point of care Isothermal-PCR Viral RNA Amplication for virus detection

DIAGNOSTIC_TEST

Public Health England Gold Standard

Reverse Transcription PCR

DIAGNOSTIC_TEST

Cambridge Validated Viral Detection Method

Reverse Transcription PCR

DIAGNOSTIC_TEST

Radiological Detection

Chest X-ray \& CT Scan detection of viral infection in the lungs

Sponsors & Collaborators

• CCTU- Cancer Theme

  lead OTHER

Principal Investigators

• Ravindra Prof. Gupta, BMBCh · University of Cambridge & Cambridge University Hospitals NHS Foundation Trust

Eligibility

Min Age

16 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-04-06

Primary Completion

2021-04-07

Completion

2021-10-07

Countries

• United Kingdom

Study Locations